Association between systolic blood pressure after thrombolysis and early neurological improvement in ischaemic stroke patients J Seok, JS Lee, KY Jeong, CM Lee Introduction: This study aimed to evaluate the relationship between systolic blood pressures (SBPs) within 12 hours after intravenous recombinant tissue plasminogen activator (rtPA) treatment and early neurological outcomes. Methods: This was a retrospective observational study of acute ischaemic stroke (AIS) patients who received intravenous rtPA administration. SBPs at the time of rtPA bolus and thereafter every hour were collected. The mean, standard deviation, and coefficient of variation values of SBP during the periods of 0-2 h, 2-6 h, and 6-12 h were calculated. The primary outcome was major neurologic improvement (MNI) at 24 hours after thrombolysis. Results: Serial measures of SBPs revealed different 12-hour courses between the patients with and without MNI. The difference of SBP tendency was statistically significant (p=0.013). In univariate analysis, patients with MNI showed lower levels of mean SBPs during the periods of 2-6 h and 6-12 h (p=0.030 and p=0.005, respectively), and higher frequency of very early neurologic improvement (VENI) at the end of rtPA infusion (p<0.001). In logistic regression analysis, VENI at 1 h, mean SBP value during 6-12 h, and atrial fibrillation were independently related to MNI at 24 h. Conclusions: SBP level during the first 12 hours after intravenous rtPA treatment may be an important clinical factor that is associated with early neurological improvement of AIS patients. (Hong Kong j.emerg.med. 2017;24:138-144) 
Introduction
Over the past decade ago, a number of efforts have been made to reduce the burden of stroke. Stroke is still the leading cause of adult disability and a very common cause of death worldwide. Intravenous administration of thrombolytic agents is the standard treatment for acute ischaemic stroke (AIS), and recombinant tissue plasminogen activator (rtPA) is now a widely accepted remedy. 1, 2 Other types of supportive care, including supplemental oxygen, patient positioning, ventilatory support, body temperature management, blood glucose control, intravenous fluid therapy, and blood pressure (BP) management have been considered. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] However, an optimal target BP in patients with ischaemic stroke has not been yet established. 13, 14 Some research has shown that high systolic BP (SBP) during acute stroke is negatively associated with both short-and long-term outcomes. 15, 16 In contrast, other studies have suggested that a decline in SBP during the acute phase of ischaemic stroke is associated with unfavourable outcomes. 17 These conflicting results may be attributable to differences in methodological design. The frequency and duration of BP measurements, the follow-up period for outcome assessment, the proportion of rtPA-treated patients, and BP variables used for evaluation were different in different studies. Also, researchers have tended to pass over the potential role of BP tendency over time course.
We investigated SBP variables, including mean, standard deviation (SD), and coefficient of variation (CV) during the initial 12 hours in the emergency department (ED) and the stroke unit. This study aimed to evaluate the relationship between 12-hour SBP variables and early neurological outcomes in AIS patients treated with intravenous rtPA.
Methods

Study setting and population
This was a retrospective observational study of AIS patients who visited the ED of an 850-bed urban university hospital. The 20-bed ED had 30,000 annual visits. The institutional review board at the hospital approved the study protocol and waived the need for patient consent because of the study's retrospective nature and the minimal patient risk involved.
The records of consecutive patients who presented with acute symptoms of stroke and received intravenous thrombolysis in the ED between January 2010 and May 2015 were reviewed. Records which lacked patient's outcome data were not included in this study. Patients who were younger than 20 years, who received intra-arterial thrombolysis or thrombectomy, who had moderate to severe disability (modified Rankin Scale [mRS] score of ≥3) before acute stroke onset, or who were admitted to the intensive care unit because of comorbid diseases, were excluded from this study.
Stroke critical pathway (CP) protocol
Our hospital has a stroke critical pathway (CP) protocol. The stroke CP team consists of emergency physicians, neurologists, neurosurgeons, and interventional radiologists. When a patient who has a neurological deficit that developed within the previous 4.5 hours visits the ED, an emergency physician assesses neurological status and activates the stroke CP protocol. The patient undergoes laboratory tests and brain computed tomography (CT) scan, and a neurologist evaluates his/her neurological status. Candidates for intravenous rtPA therapy are determined by a neurologist according to the American Heart association (AHA)/American Stroke Association (ASA) guidelines. 13 All patients who receive intravenous rtPA thrombolysis are admitted to the stroke unit for monitoring of vital signs and neurological status. Severe hypertension (SBP >180 mmHg or diastolic BP [DBP] >105 mmHg) after thrombolytic therapy is controlled as per the AHA/ASA guidelines. 13
Measurements
Baseline demographic and clinical data were collected by reviewing medical records. This included information about gender, age, height, weight, National Institutes of Health Stroke Scale (NIHSS) scores, time of rtPA administration, and vascular risk factors such as hypertension (taking antihypertensive medicine or having an SBP ≥140 mmHg or DBP ≥90 mmHg), 18 diabetes mellitus (using glucoselowering medication or having a fasting glucose level of ≥126 mg/dl), 18 atrial fibrillation, and obesity (body mass index of ≥25 kg/m 2 ). 18 Pre-stroke disability and stroke severity were assessed using the mRS score and the NIHSS score, respectively. Venous blood samples were taken before CT scans. Laboratory data included leukocyte count, haemoglobin level, total neutrophil count, total lymphocyte count, haemoglobin A1c level, and serum levels of C-reactive protein, albumin, blood urea nitrogen, creatinine, glucose, and total cholesterol.
The BP of all patients was measured in the ED and the stroke unit every 30 minutes after the beginning of rtPA administration. SBPs at the time of rtPA bolus and thereafter every hour were collected. Time duration was divided into 3 phases, considering the study design of previous report; 1) during the first 2 hours (0-2 h), 2) between 2 and 6 hours (2-6 h), and 3) between 6 and 12 hours (6-12 h). 19 The mean, SD, and CV (SD/mean x 100) of SBP during each period were calculated.
Outcome measures
Neurological outcomes were assessed using NIHSS scores. Very early neurologic improvement (VENI) at (n=29), having a severe disability before stoke onset (n=9), and having been admitted to the intensive care unit (n=1, comorbid ST elevation myocardial infarction). Consequently, 155 patients were included in this study.
The baseline characteristics of the study subjects are shown in Table 1 . The median age of the subjects was 70.0 years. Ninety-four (60.6%) patients were male. The initial NIHSS score was 9.0, and the median time interval from door to rtPA administration was 49.0 minutes. In univariate analysis, the mean value of SBP during the period of 2-6 h and 6-12 h, and frequency of VENI at 1 h were significantly different between patients with and without MNI. Frequencies of haemorrhagic transformation and antihypertensive drug use were not significantly different (Table 1) .
Serial measures of blood pressure after intravenous rtPA bolus revealed different 12-hour courses of SBP between the patients with and without MNI at 24 h. SBP in patients with MNI was consistently decreased after rtPA administration and maintained in lower levels. On the other hand, in patients without MNI, SBP was reduced at the end of rtPA infusion but returned to baseline level in an hour. As a result, the difference between SBP levels at 3, 6, 7, 8, 9, 10, and 12 hours after rtPA administration was statistically significant, respectively. The difference of serial SBP tendency assessed by RM-ANOVA was also statistically significant (p=0.013) ( Figure 1 ).
Variables with a univariate association of p<0.20 (age, atrial fibrillation, initial NIHSS score, door-to-rtPA time interval, haemoglobin level, blood urea nitrogen level, mean SBP during 2-6 h, mean SBP during 6-12 h, SD of SBP during 6-12 h, VENI at 1 h, haemorrhagic transformation, and rescue use of antihypertensives) were included into the multivariate analysis. A final logistic regression model showed that VENI at 1 h, mean SBP during 6-12 h, and atrial fibrillation were independently associated with MNI at 24 h. The Hosmer-Lemeshow goodness-of-fit test showed a p-value of 0.702, which means that the expected event rates using this model match the observed event rates ( Table 2) . 1 h was defined as an NIHSS score of 0 at the end of rtPA infusion or an improvement of ≥5 points c o m p a r e d w i t h b a s e l i n e . 2 0 H a e m o r r h a g i c transformation was defined as any petechial infarction. Major neurologic improvement (MNI) at 24 h was defined as an NIHSS score of 0-1 or an improvement of ≥8 points compared with baseline. 21 Functional outcomes were evaluated using mRS scores. All neurological and functional assessments were performed by neurologists. The primary endpoint was MNI at 24 h after intravenous rtPA treatment.
Data analysis
Data are presented as frequencies (percentages) for categorical variables and means ± standard deviations (SDs) or medians (interquartile ranges [IQRs]) for continuous variables. Univariate analyses for categorical variables were performed using Chi-square or Fisher's exact test. The Student's t-test or Mann-Whitney U-test were used for continuous variables. To compare the changes in 12-hour SBP course between patients with and without MNI, two-way repeated-measures analysis of variance (RM-ANOVA) was performed. Variables with a p-value of <0.20 in the univariate analysis were included as candidates into the multivariate analysis. A multiple logistic regression model fitted with forward stepwise selection procedure was constructed to identify clinical predictors related to MNI at 24 h. Variables that remained significant (p<0.05) in the multivariate analysis were considered as independent predictors. The fitness of the final model was evaluated using the Hosmer-Lemeshow goodness-of-fit test. All statistical analyses were performed using the SPSS statistics software (version 18.0; IBM Inc. Armonk, NY, USA).
Results
From January 2010 to May 2015, a total of 1,347 patients with acute neurological deficits (<4.5 hours) visited the ED. Five hundred thirty-seven patients were diagnosed with AIS (39.9%). Of these, 194 (36.1%) patients received intravenous rtPA therapy and were followed up. Thirty-nine patients were excluded because of intra-arterial thrombolysis or thrombectomy 
Discussion
In the present study, we found that SBP measured within 12 hours after thrombolytic therapy was associated with early neurological outcomes in patients with AIS. A constant tendency of SBP reduction between 3 and 12 hours after thrombolysis was associated with better neurological outcomes. For more than a decade, researchers have investigated the relationship between various SBP variables and stroke outcomes. Some studies used single measures of BP to evaluate whether acute-phase BP in stroke patients is associated with short-or long-term outcomes. Leonardi-Bee and colleagues observed a U-shaped relationship between a single measure of baseline SBP level taken within 48 hours after stroke onset and poor outcomes. 22 Robinson et al found that high initial SBP recorded within 24 hours after admission is associated with mortality over a 2.5-year time period. 16 On the other hand, more recent studies have been designed to measure BP repeatedly during a specific time period and to calculate the mean, SD, CV, or other values. The NINDS tPA stroke study data, in which a total of 37 BP measurements were taken during the first 24 hours, showed that short-term SBP decline (the largest difference in SBP compared to an immediately preceding time point) and overall SBP decline (the largest difference between SBP and any preceding time point) are associated with reduced likelihood of a favourable outcome at 3 months. 17 In a study analysing the VISTA database, BP and heart rate were taken at 0, 1, 2, 16, 24, 48, and 72 hours, and then haemodynamic derivatives including pulse pressure, mean arterial pressure, pulse pressure index, and rate pressure product were calculated. Changes in SBP and CV over the first 24 hours were also calculated. The study demonstrated that the magnitude of change in BP during the first day is related to poor early neurological outcomes and late functional outcomes. 23 Weiss and colleagues measured ≥50 BPs for 24 hours using an ambulatory BP-monitoring device to calculate the mean and SD SBP in acute stroke patients. They found that an elevated mean SBP is inversely associated with 1-week favourable functional outcomes and is related to long-term mortality. 15 Previous studies have produced conflicting results regarding the impact of BP on stroke outcomes. We thought these inconsistencies may be attributable to methodological differences in study design. The baseline and clinical characteristics of the study subjects, including frequency of BP measurement, calculation of BP variables, and proportion of rtPAtreated patients were different in previous studies. In addition, many researchers overlooked that BP might have a changing tendency according to time course that would be relevant to stroke outcomes. Recently, Figure 1 . Changes in systolic blood pressure of the patients with or without major neurologic improvement at 24 h. Twoway repeated-measures analysis of variance shows a significant difference (p=0.013). some investigators assessed the relationship between SBP tendency during a specific time period and neurological outcomes in stroke patients. Toyoda and colleagues performed 6 BP measurements over the initial 36 hours after admission to the ED and found that acute SBP course between 12 and 36 hours is predictive of neurological deterioration within 3 weeks of ischaemic stroke. 24 That study had a strength in that it demonstrated the relationship between the time course of BP and stroke outcomes, but also had some limitations. The type of treatment given during the first 36 hours and the 3 subsequent weeks was not precisely controlled, and confounding factors that could affect the 3-week neurological outcomes might occur later than 36 hours post-admission. In the present study, we evaluated the influence of acutephase SBP on early neurological improvement in the environment of emergency care. At least 24 BP measurements were taken during the first 12 hours in order to calculate the mean, SD, and CV of SBP. Early neurological outcomes were assessed at 24 hours to avoid the bias which may be induced by time-related confounders. According to a review of previous research, 24-hour neurological outcomes are predictive of longer-term functional outcomes. Nam and colleagues suggested that the percentage improvement at 24 hours after thrombolysis is a useful surrogate marker for prediction of 3-month outcome. 25 Because we did not design the treatment protocol, we decided to use early neurological improvement rather than late functional status as the primary endpoint for our analyses. We found that the mean SBP between 6 and 12 hours after rtPA administration was inversely associated with early neurological improvement. Additionally, the time course of SBP levels between 3 and 12 hours after thrombolysis in patients who improved early was different from that in patients who did not. This finding was consistent with that of a previous study. 24 This study has several limitations. First, data were collected and analysed retrospectively and were collected from a single center. Thus, we cannot determine a causal relationship between early-phase SBP reduction and neurological outcomes. To clearly interpret whether a reduction in SBP is a contributing factor or only a marker of neurological improvement, controlled prospective studies should be performed. However, the pre-constructed stroke CP protocol in our hospital might make up for the retrospective design of this study. The subjects received equivalent treatment for stroke according to the CP protocol. Second, we analysed only SBP during the initial 12 hours after intravenous thrombolysis. We did not evaluate the relationship between neurological outcomes and DBP or mean arterial pressure during the same period, or changes in BP after 12 hours. Thus, this study did not enough investigate the association between BP and stroke outcomes. However, previous studies have shown that stroke outcomes are generally related to SBP rather than DBP, and those findings are consistent with the results of our investigation. 24, 26, 27 Third, subgroup analysis was not conducted in this study because of the small study population. Missing information including stroke subtype, infarction size, and infarction location might have influenced our analyses.
Conclusions
SBP level during the first 12 hours after intravenous rtPA treatment may be an important clinical factor associated with early neurological improvement of AIS.
Patient whose blood pressure is not decreased at 6 hours after rtPA bolus may have lower probability of MNI at 24 h regardless of VENI at 1 h.
